Therapie des metastasierten Endometriumkarzinoms

Für die Behandlung rezidivierter und metastasierter Patientinnen mit Endometriumkarzinom stehen grundsätzlich operative, strahlentherapeutische und medikamentöse Optionen zur Verfügung. Die aktuelle AWMF-S3-Leitlinie zur Diagnostik und Therapie des Endometriumkarzinoms stellt auf der Basis der vorhandenen Literatur eine sinnvolle Vorgehensweise unter Berücksichtigung der genannten Modalitäten dar – auch unter Einsatz neuer Wirkstoffe.

Schlüsselwörter

Endometriumkarzinom - Rezidiv - Metastasen - Therapie - Checkpoint-Inhibition - MSI (Mikrosatelliteninstabilität)

• Literatur

• 1 Emons G, Steiner E, Vordermark D. et al. Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) – Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities. Geburtshilfe Frauenheilkd 2018; 78: 1089-1109 doi:10.1055/a-0715-2964
• 2 Smith CJ, Heeren M, Nicklin JL. et al. Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecol Oncol 2007; 107: 124-129
• 3 Fung-Kee-Fung M, Dodge J, Elit L. et al. Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 2006; 101: 520-529
• 4 Gadducci A, Cosio S, Fanucchi A. et al. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res 2000; 20: 1977-1984
• 5 Creutzberg CL, van Putten WL, Koper PC. et al. PORTEC Study Group. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003; 89: 201-209
• 6 Ng TY, Perrin LC, Nicklin JL. et al. Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy. Gynecol Oncol 2000; 79: 490-494
• 7 Chiantera V, Rossi M, De Iaco P. et al. Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients. Int J Gynecol Cancer 2014; 24: 156-164 doi:10.1097/IGC.0000000000000011
• 8 Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 2010; 118: 14-18
• 9 Butros SR, DelCarmen MG, Uppot RN. et al. Image-guided percutaneous thermal ablation of metastatic pelvic tumor from gynecologic malignancies. Obstet Gynecol 2014; 123: 500-505 doi:10.1097/AOG.0000000000000133
• 10 Brooks RA, Fleming GF, Lastra RR. et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin 2019; 69: 258-279 doi:10.3322/caac.21561
• 11 Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health 2014; 6: 429-435 doi:10.2147/IJWH.S40942
• 12 Kokka F, Brockbank E, Oram D. et al. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 2010; (12) CD007926
• 13 Fleming GF, Brunetto VL, Cella D. et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22: 2159-2166
• 14 Miller D, Filiaci V, Fleming G. et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study [SGO abstract LBA-1]. Gynecol Oncol 2012; 125: 771-773
• 15 Nagao S, Nishio S, Michimae H. et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol 2013; 131: 567-573
• 16 Del Carmen MG, Boruta DM, Schorge JO. Recurrent endometrial cancer. Clin Obstet Gynecol 2011; 54: 266-277 doi:10.1097/GRF.0b013e318218c6d1
• 17 Cancer Genome Atlas Research Network. Kandoth C, Schultz N, Cherniack AD. et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73 doi:10.1038/nature12113
• 18 Alsaab HO. et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations and clinical outcome. Front Pharmacol 2017; 23: 561
• 19 Mittica G, Ghisoni E, Giannone G. et al. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget 2017; 8: 90532-90544
• 20 Ott PA, Bang YJ, Bergon-Rigaud D. et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol 2017; 35: 2535-2541
• 21 Makker V, Taylor MH, Aghajanian C. et al. ESMO 2019, Proffered Paper Session 2 – Gynaecological cancers, Lenvatinib (LEN) and Pembrolizumab (PEMBRO) in Advanced Endometrial Cancer (EC) Abstract No. 9940. Ann Oncol 2019; 30 (Suppl. 05) v403-v434 doi:10.1093/annonc/mdz250
• 22 Fleming GF, Emens LA, Eder JP. et al. Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC). J Clin Oncol 2017; 35 Suppl: 5585-5585 doi:10.1200/JCO.2017.35.15_suppl.5585